BPC-157

BPC-157 is a synthetic pentadecapeptide that appears in the research literature as a fragment associated with a gastric protein preparation known as body protection compound. It is discussed mainly in preclinical studies, and it should be described as an experimental research peptide rather than an established therapy.

The peptide is usually reported as a 15-amino-acid sequence: GEPPPGKPADDAGLV. Published reviews describe it as a stable gastric pentadecapeptide derived from earlier body protection compound research, but the exact biological context and translational relevance of that origin remain less certain than the much larger preclinical literature built around the synthetic sequence itself.

No single, definitive mechanism of action has been established in humans. Preclinical papers and reviews have proposed effects on angiogenic signaling, nitric oxide-related pathways, epithelial protection, and tissue repair responses, but these mechanistic models are drawn largely from cell and animal experiments. The current evidence does not justify presenting one pathway as conclusively proven.

The evidence base is predominantly preclinical. A 2025 systematic review in orthopedic sports medicine identified 36 included studies, of which 35 were preclinical and 1 was a retrospective clinical study. Small exploratory human studies have been reported, but they do not provide the kind of replicated clinical evidence needed to treat BPC-157 as a clinically established intervention.

• Gastrointestinal injury and mucosal protection
• Tendon, ligament, muscle, and other soft-tissue healing models
• Inflammation-related animal models
• Bladder and interstitial-cystitis-related exploratory research

The main limitation is the imbalance between a large preclinical literature and sparse human data. Animal models use heterogeneous dosing, routes of administration, and outcome measures, which makes comparison difficult. Mechanistic claims are still provisional, and the available human evidence is too limited to support strong conclusions about efficacy or safety in clinical use.

• Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. doi:10.1177/15563316251355551.
• Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16). doi:10.2174/138161211796196954.
• Sikiric P, Hahm KB, Blagaic AB, et al. Stable gastric pentadecapeptide BPC 157, Robert's stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye's stress coping response: Progress, achievements, and the future. Gut and Liver. 2020;14(2):153-167. doi:10.5009/gnl18490.